Blueprint Medicines Corporation (BPMC)

We're Not Very Worried About Blueprint Medicines' (NASDAQ:BPMC) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

• 
  We're Not Very Worried About Fosterville South Exploration's (CVE:FSX) Cash Burn Rate

  Simply Wall St.
• 
  Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

  Simply Wall St.

Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective August 1, 2022, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 29,359 shares of its common stock and an aggregate of 14,675 restricted stock units (RSUs) to fourteen new employees under Blueprint Medicines' 2020 Inducement Pl

Blueprint Medicines' (BPMC) Q2 Earnings & Revenues Miss Mark

Blueprint Medicines' (BPMC) earnings and revenues fall shy of estimates for the second quarter of 2022. However, the stock is up.

• 
  BioNTech stock sinks more than 8% after profit, revenue fall below expectations

  MarketWatch
• 
  BioNTech Announces Second Quarter Financial Results and Corporate Update

  GlobeNewswire